METHOD FOR THE UTILIZATION OF AND PRODUCT CONTAINING INACTIVATED PROBIOTIC

• US 20080206212A1
• Filed: 02/22/2008
• Published: 08/28/2008
• Est. Priority Date: 02/28/2007
• Status: Active Grant

• Current Assignee: Mead Johnson Nutrition Company (Reckitt Benckiser Group PLC)
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: McMahon, Robert J., Herz, Udo, Russell, William Michael, Neu, Josef
• Granted Patent: US 9,408,818 B2
• Time in Patent Office: Days
• US Class Current: 424/93.45
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

A novel method and product utilizing or containing one or more inactivated probiotics.

Claims

1. A children'"'"'s or infant'"'"'s product comprising at least one inactivated probiotic, wherein the product is formulated to deliver from between about 1×

10⁴ to about 1×

10¹⁰ cell equivalents of inactivated probiotic per kg body weight per day to a child or infant, and wherein, other than reproductive properties, the at least one inactivated probiotic retains the cellular and molecular biological reactive properties of the viable probiotic.

2. The product of claim 1 wherein the at least one inactivated probiotic is selected from the group consisting of all known probiotics and combinations thereof.

3. The product of claim 1 wherein the at least one inactivated probiotic is selected from the group consisting of a member of the genus Lactobacillus, Bifidobacterium, and combinations thereof.

4. The product of claim 1, wherein the inactivated probiotic comprise a combination of one or more members of the genus Lactobacillus and one or more members of the genus Bifidobacterium.

5. The product of claim 1, wherein the product is formulated to deliver from between about 1×

10⁶ to about 1×

10⁹ cell equivalents per kg body weight per day.

6. The product of claim 1, wherein the product is formulated to deliver about 1×

10⁹ cell equivalents per kg body weight per day.

7. The product of claim 1, further comprising at least one viable probiotic.

8. The product of claim 7, wherein the viable probiotic is selected from the group consisting of Lactobacillus rhamnosus GG (LGG), B. animalis ssp. lactis (BB-12®

), and combinations thereof.

9. The product of claim 1, wherein the product further comprises at least one long-chain polyunsaturated fatty acid (LCPUFA).

10. The product of claim 9, wherein the LCPUFA is selected from the group consisting of docosahexaenoic acid (DHA), arachidonic acid (ARA), and combinations thereof.

11. The product of claim 10, wherein the ratio of ARA:

DHA is between about 2;

3 and about 2;

1.

12. A method for treating, preventing or reducing systemic inflammation in a subject, the method comprising administering to the subject the product of claim 1.

13. The method according to claim 12, wherein the subject is an infant.

14. The method according to claim 12, wherein the subject is a child.

15. A method for treating, preventing or reducing respiratory inflammation in a subject, the method comprising administering to the subject the product of claim 1.

16. The method according to claim 15, wherein the subject is an infant.

17. The method according to claim 14, wherein the subject is a child.

18. A method for treating, preventing or reducing systemic inflammation in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one inactivated probiotic in combination with at least one long-chain polyunsaturated fatty acid (LCPUFA).

19. A method for treating, preventing or reducing systemic inflammation in a subject, the method comprising administering to the subject a therapeutically effective amount of a combination of at least one inactivated probiotic, at least one viable probiotic, and at least one long-chain polyunsaturated fatty acid (LCPUFA).